SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Sinnott R)
 

Sökning: WFRF:(Sinnott R) > SPINK1 protein expr...

  • Flavin, RichardCenter for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, USA; Departments of Medical Oncology, Dana Farber Cancer Institute, Boston, USA (författare)

SPINK1 protein expression and prostate cancer progression

  • Artikel/kapitelEngelska2014

Förlag, utgivningsår, omfång ...

  • Philadelphia, USA :American Association for Cancer Research,2014
  • printrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:oru-41406
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-41406URI
  • https://doi.org/10.1158/1078-0432.CCR-13-1341DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:129792991URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • Purpose: SPINK1 overexpression has been described in prostate cancer and is linked with poor prognosis in many cancers. The objective of this study was to characterize the association between SPINK1 overexpression and prostate cancer-specific survival.Experimental design: The study included 879 participants in the U.S. Physicians' Health Study and Health Professionals Follow-Up Study, diagnosed with prostate cancer (1983-2004) and treated by radical prostatectomy. Protein tumor expression of SPINK1 was evaluated by immunohistochemistry on tumor tissue microarrays.Results: Seventy-four of 879 (8%) prostate cancer tumors were SPINK1 positive. Immunohistochemical data were available for PTEN, p-Akt, pS6, stathmin, androgen receptor (AR), and ERG (as a measure of the TMPRSS2:ERG translocation). Compared with SPINK1-negative tumors, SPINK1-positive tumors showed higher PTEN and stathmin expression, and lower expression of AR (P < 0.01). SPINK1 overexpression was seen in 47 of 427 (11%) ERG-negative samples and in 19 of 427 (4%) ERG-positive cases (P = 0.0003). We found no significant associations between SPINK1 status and Gleason grade or tumor stage. There was no association between SPINK1 expression and biochemical recurrence (P = 0.56). Moreover, there was no association between SPINK1 expression and prostate cancer mortality (there were 75 lethal cases of prostate cancer during a mean of 13.5 years follow-up; HR = 0.71; 95% confidence interval, 0.29-1.76).Conclusions: Our results suggest that SPINK1 protein expression may not be a predictor of recurrence or lethal prostate cancer amongst men treated by radical prostatectomy. SPINK1 and ERG protein expression do not seem to be entirely mutually exclusive, as some previous studies have suggested.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Pettersson, AndreasKarolinska Institutet (författare)
  • Hendrickson, Whitney K.Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Fiorentino, MichelangeloCenter for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, USA (författare)
  • Finn, StephenCenter for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, USA; Department of Histopathology, St. James's Hospital, Trinity College Dublin Medical School, Dublin, Ireland (författare)
  • Kunz, LaurenChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Judson, Gregory L.Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Lis, RosinaCenter for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, USA (författare)
  • Bailey, DyaneCenter for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, USA (författare)
  • Fiore, ChristopherCenter for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, USA (författare)
  • Nuttall, ElizabethChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Martin, Neil E.Departments of Radiation Oncology, Dana Farber Cancer Institute, Boston, USA (författare)
  • Stack, EdwardCenter for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, USA (författare)
  • Penney, Kathryn L.Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Rider, Jennifer R.Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Sinnott, JenniferChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Sweeney, ChristopherDepartments of Medical Oncology, Dana Farber Cancer Institute, Boston, USA (författare)
  • Sesso, Howard DDivision of Preventive Medicine, Brigham and Women's Hospital, Boston, USA (författare)
  • Fall, Katja,1971-Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA(Swepub:oru)kafl (författare)
  • Giovannucci, EdwardChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Kantoff, PhilipDepartments of Medical Oncology, Dana Farber Cancer Institute, Boston, USA (författare)
  • Stampfer, MeirChanning Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Loda, MassimoCenter for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, USA; Departments of Medical Oncology, Dana Farber Cancer Institute, Boston, USA (författare)
  • Mucci, Lorelei A.Channing Division of Network Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, USA; Department of Epidemiology, Harvard School of Public Health, Boston, USA (författare)
  • Karolinska InstitutetCenter for Molecular Oncologic Pathology, Dana Farber Cancer Institute, Boston, USA; Departments of Medical Oncology, Dana Farber Cancer Institute, Boston, USA (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Clinical Cancer ResearchPhiladelphia, USA : American Association for Cancer Research20:18, s. 4904-111078-04321557-3265

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy